Product Description
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Bulgaria | Chile | Dominican Republic | Egypt | Hong Kong | Hungary | Indonesia | Ireland | Malaysia | New Zealand | Norway | Pakistan | Philippines | Poland | Portugal | Russia | South Africa | Spain | Taiwan | Thailand | United Arab Emirates | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Centre of Postgraduate Medical Education
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Atrial Fibrillation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05720572 |
AnProAF | P4 |
Recruiting |
Atrial Fibrillation |
2025-09-01 |
2023-02-10 |
Primary Endpoints|Treatments |
|
NCT01527279 |
AnPAF | P4 |
Completed |
Atrial Fibrillation |
2015-01-01 |
2023-03-30 |
Recent News Events
Date |
Type |
Title |
|---|
